A series of cardiometabolic-related news items has been observed from Arrowhead, Structure Therapeutics, Senseonics, Tandem Diabetes Care, and Pfizer. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed by Pfizer, Madrigal Pharmaceuticals, Novo Nordisk, Vertex Pharmaceuticals, and Cytokinetics. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related new items has been observed from Pfizer, Novo Nordisk, Merck, Amgen, and Zonsen PepLib Biotech/Lilly. Below, FENIX provides highlights and insights for the respective news items.
On the first day of JPM 2026, FENIX has provided coverage of presentations by major CVRM companies, including Dexcom, Arrowhead, Novartis, Alnylam, Pfizer, Sanofi, Cytokinetics, Medtronic, Madrigal, and Regeneron. Additionally, three cardiometabolic-related news items have been observed: Skye Biosciences released its 2026 corporate outlook (view press release); BioAge Labs announced updated Ph1 data of its NLRP3i for CV risk reduction (view press release); and Kailera announced it randomized the first patients in its Ph3 KaiNETIC program (view press release). Below, FENIX provides highlights and insights for the respective news items.
Pfizer announced it entered into a definitive agreement to acquire Metsera, providing the company access to Metsera’s obesity portfolio, including MET-097i (QW/QM SC GLP-1RA), MET-233i (QM SC amylin analog), MET-224o (oral GLP-1RA), and MET-097o (oral GLP-1RA). An associated call was held (view slides). The deal comes following a series of setbacks to Pfizer’s own obesity development program, including the danuglipron discontinuation earlier this year (previous FENIX insight). Below, FENIX provides an overview of the acquisition, commentary from Pfizer, and insight into how this move transforms the future obesity landscape.
Three cardiometabolic-related news items have been observed: AstraZeneca (press release; slides), Merck (press release; slides), and Metsera (view press release) released their respective Q2 ‘25 earnings. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news has been observed from FDA, Lilly/Verve, Metsera, Medtronic/MiniMed, and Allurion Technologies. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Metsera, Merck, Novo Nordisk, and Alnylam Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related items has been observed from Lilly, Metsera, Akero Therapeutics, Madrigal Pharmaceuticals, and Roche. Below, FENIX provides highlights and insights into the respective news items.
A series of cardiometabolic-related news items has been observed from Metsera, Beta Bionics, Viking Therapeutics, Vivani Medical, and Dexcom. Below, FENIX provides highlights and insights for the respective news items including the first-ever earnings calls from Metsera and Beta Bionics.